Today (27th), Director of the Department of Health, Luk Ching-mo, led a delegation to complete the final day of this visit in Beijing.

During the visit to the National Pharmaceutical Regulatory Authority, Luk Ching-mo stated that the Hong Kong government will take a more proactive, more aggressive, and more efficient approach to leverage Hong Kong's medical advantages, and jointly establish a regional clinical trial collaboration platform with Shenzhen based on the Bay Area's population of over 86 million. This platform aims to attract more local and overseas pharmaceutical and medical instrument companies to choose Hong Kong for research and clinical trials, establish capabilities, acceptance, and status at different stages, and ensure that Hong Kong's final drug and medical device approval mechanism is internationally and domestically recognized.

Luk Ching-mo revealed that since the implementation of the "1+1" new drug approval mechanism, the Department of Health has received inquiries from over 70 pharmaceutical factories and more than 250 queries, including many overseas and mainland pharmaceutical factories, and has approved five new drug applications under the mechanism. In addition, on June 5th this year, the Hong Kong government established the Preparatory Office of the "Hong Kong Drug and Medical Device Regulation Center" at the Department of Health, conducting overall research and planning for a drug and medical device regulatory and approval system suitable for Hong Kong, and proposing recommendations and steps for the establishment of the "Medical Device Regulation Center".